Table 2.

The 19 SNPs with the lowest unadjusted P values that were associated with the OS of lung cancer patients treated with platinum compounds

LCL GWASClinical Study
SNPChr.SNP positionMAFRaPMAFHR (95% CI)bP
Among NSCLC patients
rs12872765360834580.242−0.2474.72E-050.0951.36 (1.15–1.61)0.0004
rs9405302c682280490.3940.2671.08E-050.2111.22 (1.08–1.37)0.001
rs80646301737892400.1520.2513.61E-050.1870.82 (0.71–0.94)0.004
rs5970160c231508446540.170.2592.25E-050.1261.17 (1.05–1.31)0.006
rs1946518111115406680.3840.2495.55E-050.3960.87 (0.78–0.96)0.008
rs2440915c10613437780.0580.2494.10E-050.0291.41 (1.08–1.83)0.012
rs5952066c231466928400.1780.2426.92E-050.2001.14 (1.03–1.26)0.014
rs901893c582280490.3530.2398.53E-050.3371.14 (1.02–1.27)0.018
rs11169748c12498654380.0620.2379.60E-050.0111.75 (1.03–2.97)0.039
Among SCLC patients
rs12669805c7795090550.1880.2533.32E-050.0243.42 (1.56–7.48)0.002
rs6092092c20532916850.0760.2494.28E-050.0067.74 (1.85–32.30)0.005
rs283353721321353330.0740.2543.03E-050.0360.40 (0.20–0.79)0.008
rs7620841c31874250140.060.2426.77E-050.0521.80 (1.12–2.89)0.015
rs1921626c2770255740.2050.2389.00E-050.0841.57 (1.09–2.26)0.015
rs1704308812761037180.104−0.2388.88E-050.0262.21 (1.16–4.22)0.016
rs753921c4355798940.2310.2398.69E-050.2741.31 (1.05–1.64)0.018
rs761837331778197130.446−0.2553.17E-050.3781.27 (1.02–1.57)0.030
rs59160722354061960.3430.2475.04E-050.4420.84 (0.70–1.00)0.046
rs10517364c4355628530.2460.2582.12E-050.3101.23 (1.00–1.52)0.050
  • aR values represent correlation coefficients for the associations between SNPs and cisplatin IC50.

  • bIf HR > 1, patients carrying the minor allele had worse OS.

  • cSNP showed a concordant association with the IC50 and OS phenotypes.